Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...

Descripció completa

Dades bibliogràfiques

Autors principals:	Khalid Alhazzani, Meshal Alsahli, Ahmed Z Alanazi, Mohammad Algahtani, Ahmad A Alenezi, Ali Alhoshani, Mohammed Alqinyah, Abdullah S. Alhamed, Khaled Alhosaini
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2023-10-01
Col·lecció:	Saudi Pharmaceutical Journal
Matèries:	Erlotinib Cabozantinib VEGF EGFR Combination therapy A549
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1319016423002517
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!